In Wednesday’s Wall Street session, Kairos Pharma Ltd (AMEX:KAPA) shares traded at $0.52, up 15.69% from the previous session.
KAPA stock price is now -34.73% away from the 50-day moving average and -59.70% away from the 200-day moving average. The market capitalization of the company currently stands at $8.77M.
In other news, Murali Ramachandran, VP of Research and Development bought 200 shares of the company’s stock on Nov 25 ’24. The stock was bought for $318 at an average price of $1.59. Upon completion of the transaction, the VP of Research and Development now directly owns 133,057 shares in the company, valued at $69189.64. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 22 ’24, Chief Financial Officer Samuelson Doug bought 2,500 shares of the business’s stock. A total of $3,750 was incurred on buying the stock at an average price of $1.50. This leaves the insider owning 60,796 shares of the company worth $31613.92. A total of 57.73% of the company’s stock is owned by insiders.
During the past 12 months, Kairos Pharma Ltd has had a low of $0.40 and a high of $4.00. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 7.52, and a quick ratio of 7.52. The fifty day moving average price for KAPA is $0.79758 and a two-hundred day moving average price translates $1.2919333 for the stock.
The latest earnings results from Kairos Pharma Ltd (AMEX: KAPA) was released for 2025-03-31.
